DOI QR코드

DOI QR Code

Overexpression of EGFR Protein in Bruneian Lung Cancer Patients

  • Han, Yu Hao (PAPRSP Institute of Health Sciences, University of Brunei Darussalam) ;
  • Hamid, Mas R.W. Abdul (PAPRSP Institute of Health Sciences, University of Brunei Darussalam) ;
  • Telisinghe, Pemasiri Upali (Pathology Department, Raja Isteri Pengiran Anak Saleha Hospital) ;
  • Hussin, Juniadah Binti Haji (Pathology Department, Raja Isteri Pengiran Anak Saleha Hospital) ;
  • Mabruk, Mohamed (PAPRSP Institute of Health Sciences, University of Brunei Darussalam)
  • Published : 2015.02.04

Abstract

Background: Lung cancer is the leading cause of cancer death in Brunei Darussalam, accounting for almost 20% of the total. The epidermal growth factor receptor (EGFR) is a member of the erbB family of tyrosine kinase receptor proteins, which includes c-erbb2(HER2/neu), erb-B3, and erb-B4. EGFR overexpression is found in a third of all epithelial cancers, often associated with a poor prognosis. Materials and Methods: Protein expression of EGFR in 27 cases of lung cancer tissue samples and 9 cases of normal lung tissue samples was evaluated using an immunohistochemical approach. Results: The results demonstrated significant increase and overexpression of EGFR in Bruneian lung cancer tissue samples in comparison to normal lung tissue. However, there was no significant relationship between clinicopathologic variables (age and sex) of patients and EGFR protein expression. Conclusions: EGFR is overexpressed in Bruneian lung cancer patient tissue samples in comparison to normal lung tissue samples. This may indicate that EGFR protein over expression plays an important role in the genesis of this type of cancer in Brunei Darussalam.

Keywords

Lung cancer;EGFR;immunohistichemistry;overexpression

References

  1. Yoshida K, Tosaka A, Takeuchi S, et al. (1994).: Epidermal growth factor receptor content in human renal cell carcinomas. Cancer, 73, 1913-8. https://doi.org/10.1002/1097-0142(19940401)73:7<1913::AID-CNCR2820730723>3.0.CO;2-5
  2. Zhao N, Zheng SY, Yang JJ, et al (2014). Lung adenocarcinoma harboring concomitant egfr mutation and eml4-alk fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review. Clin Lung Cancer, [Epub ahead of print].
  3. Hoang MP, Sahin AA, Ordonez NG, et al (2000). HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol, 113, 852-9. https://doi.org/10.1309/VACP-VLQA-G9DX-VUDF
  4. Li F, Liu Y, Chen H, Liao D, et al (2011). EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features. J Exp Clin Cancer Res, 30, 27. https://doi.org/10.1186/1756-9966-30-27
  5. Mutti A. (2008). Molecular diagnosis of lung cancer: an overview of recent developments. ACTA BIOMED (2008), 79, Suppl 1; p.11.
  6. Ministry of Health, Brunei Darussalam. (2013) Health information booklet 2011. Available from: http://www.moh.gov.bn/satisticshealthguidelines/indicators.htm. [Accessed: 7 September 2013]
  7. Oda K, Matsuoka Y, Funahashi A, et al (2005). A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol, 1, 10.
  8. Pauletti G, Dandekar S, Rong H, et al (2000). Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol, 18, 3651-64.
  9. Phsaki Y; Tanno S; Fujita Y; et al (2000). Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep, 7, 603-7.
  10. Soh J, Okumura N, Lockwood WW, Yamamoto H, et al (2009). Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One, 14, 7464.
  11. Srisam-Ang K, Podhipak A, Narksawat K, et al (2005). Survival of patients with advanced non-small-cell lung cancer at ubon ratchathani cancer center, Thailand. Southeast Asian J Trop Med Public Health, 36, 994-1006
  12. Scagliotti GV, Selvaggi G, Novello S, et al. (2004) The Biology of Epidermal Growth Factor Receptor in Lung Cancer. Clin Cancer Res, 10, 4227-32. https://doi.org/10.1158/1078-0432.CCR-040007
  13. Santos, CG; Shepherd FA; Tsao MS(2002). EGFR mutations and lung cancer. Oncologist, 7, 431-39.
  14. Salomon DS, Brandt R, Ciardiello F, et al (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol, 19, 183-232. https://doi.org/10.1016/1040-8428(94)00144-I
  15. Sanchez CEJ (2004), Overall long-term survival in lung cancer analyzed in 610 unselected patients. Arch Bronconeumol, 40, 268-74.
  16. Tubbs RR, Pettay JD, Roche PC, et al (2001). Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol, 19, 2714-21.
  17. Wang T; Nelson RA; BogardusA; Grannis FW Jr.(2010) Fiveyear lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer, 116, 1518-25. https://doi.org/10.1002/cncr.24871
  18. World Health Organization (2013). Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx [Accessed: 1st June 2014].
  19. Arteaga CL (2006). EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. Cancer Cell, 9, 421-3. https://doi.org/10.1016/j.ccr.2006.05.014
  20. Abdel Salam I, Gaballa HE, Abdel Wahab N. (2009). Serum levels of epidermal growth factor and HER-2 neu in non small-cell lung cancer: prognostic correlation. Med Oncol, 26, 161-6. https://doi.org/10.1007/s12032-008-9102-y
  21. American Cancer Society (2014). Lung Cancer [Online] Available from: http://www.cancer.org/cancer/lungcancer/index [Accessed: 1st June 2014].
  22. Barghi L, Asgari D, Barar J, et al (2014). Synthesis, characterization and in vitro anti-tumoral evaluation of erlotinib-PCEC nanoparticles. Asian Pac J Cancer Prev, 15, 10281-7. https://doi.org/10.7314/APJCP.2014.15.23.10281
  23. Baek JH, Sun JM, Min YJ, et al (2014). Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea. Lung Cancer, [Epub ahead of print]
  24. Cooper WA, Yu B, Yip PY, et al (2013). EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma. J Clin Pathol, 66, 744-8. https://doi.org/10.1136/jclinpath-2013-201607
  25. Dacic S, Flanagan M, Cieply K,et al. (2006). Significance of EGFR protein expression and gene amplification in nonsmall cell lung carcinoma. Am J Clin Pathol, 125, 860-5. https://doi.org/10.1309/H5UW6CPCWWC92241
  26. Ettinger DS (2006). Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. Oncologist, 11, 358-73. https://doi.org/10.1634/theoncologist.11-4-358
  27. Ekrem Cengiz Seyhan, Sedat A, Erdogan C (2010). Prognostic value of epidermal growth factor receptor expression in operable non-small cell lung carcinoma. Multidiscip Respir Med, 5, 305-11. https://doi.org/10.1186/2049-6958-5-5-305
  28. Grandis JR, Melhem MF, Barnes M, et al (1996). Quantitative immunohistochemical analysis of transforming growth factor alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer, 78, 1284-92. https://doi.org/10.1002/(SICI)1097-0142(19960915)78:6<1284::AID-CNCR17>3.0.CO;2-X
  29. Gupta R, Dastane AM, Forozan F, et al (2009). Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method. Mod Pathol, 22, 128-33. https://doi.org/10.1038/modpathol.2008.182
  30. Hsieh MS, Jhuang JY, Hua SF, et al (2015). Histologic evolution from adenocarcinoma to squamous cell carcinoma after gefitinib treatment. Ann Thorac Surg, 99, 316-9. https://doi.org/10.1016/j.athoracsur.2014.02.075
  31. Han J, Lee SH, Lee GK, et al (2015). Phase I/II study of gefitinib ($Iressa^{(R)}$) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol, [Epub ahead of print]
  32. Hirsch FR, Varella-Garcia M, Bunn PA, et al (2003). Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol, 21, 3798-3807. https://doi.org/10.1200/JCO.2003.11.069
  33. Hirsch F; Scagliotti GV; Langer CJ; et al (2003). Epidermal growth factor family of receptors in preneoplasia and lung cancer. perspectives for targeted therapies. Lung Cancer, 41, 29-41.

Cited by

  1. Advances in studies of tyrosine kinase inhibitors and their acquired resistance vol.17, pp.1, 2018, https://doi.org/10.1186/s12943-018-0801-5